Science & Product
Atopic Dermatitis
Atopic Dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition that affects up to 20% of children and 3% of adults worldwide. It is characterized by dry, itchy, and inflamed skin that significantly impacts quality of life.
Current treatments often rely on topical corticosteroids and immunosuppressants, which can carry significant side effects with long-term use. There remains a substantial unmet need for safe, effective, and well-tolerated topical treatments, particularly for pediatric patients.
The Untapped Potential of Fexofenadine
Topical Fexofenadine
Fexofenadine is a well-known, safe, and effective second-generation antihistamine used worldwide in oral form. Celfex is developing a novel proprietary topical formulation that delivers Fexofenadine directly to the skin, targeting the multi-factorial nature of Atopic Dermatitis.
Our approach leverages the established safety profile of Fexofenadine while unlocking its previously unexplored potential as a topical multi-action agent for eczema treatment.
Multi-Action Benefits
Topical Fexofenadine addresses multiple pathways involved in Atopic Dermatitis pathology.
H1R Blocking
Fexofenadine is a well-established selective H1-receptor antagonist. Topical application targets histamine-mediated itch and inflammation directly at the site of disease.
Anti-inflammatory Control
Beyond antihistamine activity, topical Fexofenadine demonstrates anti-inflammatory properties that help reduce the redness and swelling associated with eczema flares.
Dysbiosis Control
The formulation helps restore microbial balance on the skin surface, addressing the dysbiosis commonly observed in Atopic Dermatitis patients.
Moisture Retention
Enhanced skin hydration through improved barrier function, helping to maintain moisture levels critical for eczema management.
Barrier Repair
Supports restoration of the compromised skin barrier characteristic of Atopic Dermatitis, reducing transepidermal water loss.
Upregulation of Antimicrobial Peptides
Promotes the skin's natural defense mechanisms by upregulating antimicrobial peptides, which are often deficient in AD patients.
Intellectual Property
Celfex AB holds a comprehensive patent portfolio covering the topical application of Fexofenadine for Atopic Dermatitis. Our IP is sub-licensed from MHG Management GmbH and provides strong protection for our novel formulation and therapeutic approach across key global markets.